Page last updated: 2024-11-12

arginyl-glycyl-aspartyl-valine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9933202
CHEMBL ID397915
MeSH IDM0229788

Synonyms (20)

Synonym
NCGC00167170-01
2-{2-[2-(2-amino-5-guanidino-pentanoylamino)-acetylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid
(2s)-2-[(2s)-2-{2-[(2s)-2-amino-5-carbamimidamidopentanamido]acetamido}-3-carboxypropanamido]-3-methylbutanoic acid
rgdv
bdbm50241181
arg-gly-asp-val
(s)-2-{(s)-2-[2-((s)-2-amino-5-guanidino-pentanoylamino)-acetylamino]-3-carboxy-propionylamino}-3-methyl-butyric acid
2-[1-[1-amino-4-amino(imino)methylamino-(1s)-butylcarboxamidomethylcarboxamido]-2-carboxy-(1s)-ethylcarboxamido]-3-methyl-(2s)-butanoic acid
rgdv tetrapeptide
CHEMBL397915 ,
arginyl-glycyl-aspartyl-valine
93674-99-8
n-(n-(n-l-arginylglycyl)-l-alpha-aspartyl)-l-valine
l-valine, n-(n-(n-l-arginylglycyl)-l-alpha-aspartyl)-
DTXSID30239528
(2s)-2-[[(2s)-2-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoic acid
l-valine,l-arginylglycyl-l-a-aspartyl-
(6s,12s,15s)-1,6-diamino-12-(carboxymethyl)-1-imino-15-isopropyl-7,10,13-trioxo-2,8,11,14-tetraazahexadecan-16-oic acid
CS-0144052
HY-P3052
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrin beta-3Homo sapiens (human)IC50 (µMol)10.00000.00010.632310.0000AID92690
Integrin alpha-IIbHomo sapiens (human)IC50 (µMol)10.00000.00010.730910.0000AID92690
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)IC50 (µMol)10.00000.00021.014010.0000AID92690
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (106)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (32)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (37)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (56)

Assay IDTitleYearJournalArticle
AID223375Inhibition of platelet aggregation in human-platelet rich plasma(h-PRP) induced by adenosine 5'-diphosphate-(ADP)1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Low molecular weight, non-peptide fibrinogen receptor antagonists.
AID170337Effect on the wet thrombus weight in male wistar rat was determined(in vivo)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID165505Maximum rate of PAF induced platelet aggregation was determined in rabbit blood at a dose of 10-5 mol/L (in vitro)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID381992Inhibition of 10 uM adenosine diphosphate-induced platelet aggregation in rabbit blood2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID291690Effect on liver weight in ovariectomized mouse at 0.110 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID381983Nitric oxide radical scavenging activity in rat aortic strip assessed as inhibition of acetylcholine-induced vasorelaxation at 1 uM2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID270586Effect on PAF-induced platelet aggregation in rabbit platelet-rich plasma at 0.1 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID291692Effect on uterus weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID165502Maximum rate of ADP induced platelet aggregation was determined in rabbit blood at a dose of 10-5 mol/L (in vitro)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID291691Effect on spleen weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID301634Inhibition of PAF-induced platelet aggregation in rabbit platelet rich plasma at 0.1 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
AID183997Compound tested for inhibition of Ach-induced vasorelaxation was determined in rat aortic strips2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID301635Antithrombotic effect in Wistar rat assessed as reduction in wet thrombus mass at 5 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
AID270585Effect on PAF-induced platelet aggregation in rabbit platelet-rich plasma at 1 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID291689Effect on lung weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID291688Effect on mineral content in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID381999Antithrombotic activity in Wistar rat assessed as wet thrombus weight at 5 umol/kg2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID291682Effect on serum phosphorus level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID291685Effect on femur length in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID381993Inhibition of 1 uM adenosine diphosphate-induced platelet aggregation in rabbit blood2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID291686Effect on calcium level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID270587Decrease in weight of wet thrombus in rat at 5 umol/kg2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID381997Inhibition of 0.1 uM platelet activating factor-induced platelet aggregation in rabbit blood2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID291683Effect on dry weight of femurs in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID382240Nitric oxide radical scavenging activity in rat aortic strip assessed as inhibition of acetylcholine-induced vasorelaxation at 10 uM2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID270584Effect on PAF-induced platelet aggregation in rabbit platelet-rich plasma at 10 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID381996Inhibition of 1 uM platelet activating factor-induced platelet aggregation in rabbit blood2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID382001Antithrombotic activity in Wistar rat assessed as wet thrombus weight at 5 umol/kg2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID270588Decrease in weight of dry thrombus in rat at 5 umol/kg2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID291684Effect on femur ash weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID270581Effect on ADP-induced platelet aggregation in rabbit platelet-rich plasma at 10 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID165506Maximum rate of PAF induced platelet aggregation was determined in rabbit blood at a dose of 10-6 mol/L (in vitro)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID301629Inhibition of ADP-induced platelet aggregation in rabbit platelet rich plasma at 10 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
AID381995Inhibition of 10 uM platelet activating factor-induced platelet aggregation in rabbit blood2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID291687Effect on phosphorus level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID301630Inhibition of ADP-induced platelet aggregation in rabbit platelet rich plasma at 1 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
AID170332Effect on the dry thrombus weight in male wistar rat was determined(in vivo)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID165507Maximum rate of PAF induced platelet aggregation was determined in rabbit blood at a dose of 10-7 mol/L (in vitro)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID223377Inhibition of platelet aggregation in human-platelet rich plasma(h-PRP) induced by thrombin1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Low molecular weight, non-peptide fibrinogen receptor antagonists.
AID291679Increase in body weight in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID223376Inhibition of platelet aggregation in human-platelet rich plasma(h-PRP) induced by collagen1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Low molecular weight, non-peptide fibrinogen receptor antagonists.
AID92690Ability to inhibit the aggregation of fixed human platelets1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Design of a new class of orally active fibrinogen receptor antagonists.
AID270582Effect on ADP-induced platelet aggregation in rabbit platelet-rich plasma at 1 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID301636Antithrombotic effect in Wistar rat assessed as reduction in dry thrombus mass at 5 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
AID381984Nitric oxide radical scavenging activity in rat aortic strip assessed as inhibition of acetylcholine-induced vasorelaxation at 100 uM2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID291681Effect on serum calcium level in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID301633Inhibition of PAF-induced platelet aggregation in rabbit platelet rich plasma at 1 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
AID301631Inhibition of ADP-induced platelet aggregation in rabbit platelet rich plasma at 0.1 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
AID270583Effect on ADP-induced platelet aggregation in rabbit platelet-rich plasma at 0.1 uM2006Bioorganic & medicinal chemistry letters, Sep-01, Volume: 16, Issue:17
Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates.
AID381994Inhibition of 0.1 uM adenosine diphosphate-induced platelet aggregation in rabbit blood2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
A class of novel nitronyl nitroxide labeling basic and acidic amino acids: synthesis, application for preparing ESR optionally labeling peptides, and bioactivity investigations.
AID165504Maximum rate of ADP induced platelet aggregation was determined in rabbit blood at a dose of 10-7 mol/L (in vitro)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID165503Maximum rate of ADP induced platelet aggregation was determined in rabbit blood at a dose of 10-6 mol/L (in vitro)2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis and bioactivities of nitronyl nitroxide and RGD containing pseudopeptides.
AID73164Inhibition of fibrinogen binding to immobilized fibrinogen receptor1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Low molecular weight, non-peptide fibrinogen receptor antagonists.
AID217303Inhibition of fibrinogen binding to immobilized vitronectin receptor1992Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23
Low molecular weight, non-peptide fibrinogen receptor antagonists.
AID291680Effect on serum ALP lavel in ovariectomized mouse at 0.1103 mmol/kg, ip once daily for 4 weeks2007Journal of medicinal chemistry, Jul-12, Volume: 50, Issue:14
Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates.
AID301632Inhibition of PAF-induced platelet aggregation in rabbit platelet rich plasma at 10 umol/L2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-beta-carboline RGD peptidomimetic conjugates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (33.33)18.2507
2000's6 (40.00)29.6817
2010's3 (20.00)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.68 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]